A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

NNC9204-1177

A single dose administered subcutaneously ( s.c. under the skin)

DRUG

Placebo

A single dose administered subcutaneously ( s.c. under the skin)

Trial Locations (1)

Novo Nordisk Investigational Site, Baltimore